Literature DB >> 35858326

Sox9 directs divergent epigenomic states in brain tumor subtypes.

Debosmita Sardar1, Hsiao-Chi Chen2, Amanda Reyes1,3, Srinidhi Varadharajan4, Antrix Jain5, Carrie Mohila6,7, Rachel Curry1,2, Brittney Lozzi1,8, Kavitha Rajendran1, Alexis Cervantes1, Kwanha Yu1, Ali Jalali9, Ganesh Rao9, Stephen C Mack4, Benjamin Deneen1,2,9.   

Abstract

Epigenetic dysregulation is a universal feature of cancer that results in altered patterns of gene expression that drive malignancy. Brain tumors exhibit subtype-specific epigenetic alterations; however, the molecular mechanisms responsible for these diverse epigenetic states remain unclear. Here, we show that the developmental transcription factor Sox9 differentially regulates epigenomic states in high-grade glioma (HGG) and ependymoma (EPN). Using our autochthonous mouse models, we found that Sox9 suppresses HGG growth and expands associated H3K27ac states, while promoting ZFTA-RELA (ZRFUS) EPN growth and diminishing H3K27ac states. These contrasting roles for Sox9 correspond with protein interactions with histone deacetylating complexes in HGG and an association with the ZRFUS oncofusion in EPN. Mechanistic studies revealed extensive Sox9 and ZRFUS promoter co-occupancy, indicating functional synergy in promoting EPN tumorigenesis. Together, our studies demonstrate how epigenomic states are differentially regulated in distinct subtypes of brain tumors, while revealing divergent roles for Sox9 in HGG and EPN tumorigenesis.

Entities:  

Keywords:  ependymoma; epigenetics; high-grade glioma; histone; transcription

Mesh:

Substances:

Year:  2022        PMID: 35858326      PMCID: PMC9303974          DOI: 10.1073/pnas.2202015119

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  50 in total

1.  EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.

Authors:  Nicolò Riggi; Birgit Knoechel; Shawn M Gillespie; Bradley E Bernstein; Miguel N Rivera; Esther Rheinbay; Gaylor Boulay; Mario L Suvà; Nikki E Rossetti; Wannaporn E Boonseng; Ozgur Oksuz; Edward B Cook; Aurélie Formey; Anoop Patel; Melissa Gymrek; Vishal Thapar; Vikram Deshpande; David T Ting; Francis J Hornicek; G Petur Nielsen; Ivan Stamenkovic; Martin J Aryee
Journal:  Cancer Cell       Date:  2014-10-30       Impact factor: 31.743

2.  Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1.

Authors:  Dan Zhu; Stephen B Hunter; Paula M Vertino; Erwin G Van Meir
Journal:  Cancer Res       Date:  2011-07-01       Impact factor: 12.701

3.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

4.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

5.  PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.

Authors:  Joost H A Martens; Arie B Brinkman; Femke Simmer; Kees-Jan Francoijs; Angela Nebbioso; Felicetto Ferrara; Lucia Altucci; Hendrik G Stunnenberg
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

6.  A method for stable transgenesis of radial glia lineage in rat neocortex by piggyBac mediated transposition.

Authors:  Fuyi Chen; Joseph LoTurco
Journal:  J Neurosci Methods       Date:  2012-04-11       Impact factor: 2.390

7.  Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.

Authors:  Gaspar J Kitange; Ann C Mladek; Mark A Schroeder; Jenny C Pokorny; Brett L Carlson; Yuji Zhang; Asha A Nair; Jeong-Heon Lee; Huihuang Yan; Paul A Decker; Zhiguo Zhang; Jann N Sarkaria
Journal:  Cell Rep       Date:  2016-03-10       Impact factor: 9.423

Review 8.  Epigenomic Reprogramming as a Driver of Malignant Glioma.

Authors:  Richard E Phillips; Alexey A Soshnev; C David Allis
Journal:  Cancer Cell       Date:  2020-09-10       Impact factor: 31.743

9.  ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma.

Authors:  Amir Arabzade; Yanhua Zhao; Srinidhi Varadharajan; Hsiao-Chi Chen; Selin Jessa; Bryan Rivas; Austin J Stuckert; Minerva Solis; Alisha Kardian; Dana Tlais; Brian J Golbourn; Ann-Catherine J Stanton; Yuen San Chan; Calla Olson; Kristen L Karlin; Kathleen Kong; Robert Kupp; Baoli Hu; Sarah G Injac; Madeline Ngo; Peter R Wang; Luz A De León; Felix Sahm; Daisuke Kawauchi; Stefan M Pfister; Charles Y Lin; H Courtney Hodges; Irtisha Singh; Thomas F Westbrook; Murali M Chintagumpala; Susan M Blaney; Donald W Parsons; Kristian W Pajtler; Sameer Agnihotri; Richard J Gilbertson; Joanna Yi; Nada Jabado; Claudia L Kleinman; Kelsey C Bertrand; Benjamin Deneen; Stephen C Mack
Journal:  Cancer Discov       Date:  2021-03-19       Impact factor: 39.397

10.  SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance.

Authors:  Zhen Wang; Xiaoshan Xu; Nan Liu; Yingduan Cheng; Weilin Jin; Pengxing Zhang; Xin Wang; Hongwei Yang; Hui Liu; Yanyang Tu
Journal:  Oncotarget       Date:  2017-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.